ASCO 2023 | The value of the liquid biopsy compared to traditional melanoma screening modalities

Helen Rizos, PhD, Macquarie University, Sydney, Australia, shares her opinion on the unique advantages liquid biomarkers hold over traditional tissue biopsies in melanoma diagnosis and treatment. Prof. Rizos highlights the minimally invasive opportunity the liquid biopsy offers to analyze tumor load as well as it’s capacity to longitudinally measure the response of patients to treatment. Furthermore, liquid biopsies also allow healthcare professionals to detect tumors earlier than other traditional imaging modalities. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.